Genscript Biotech Corporation (GNNSF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -248.71 Million USD | 14.76% |
| 2022 | -355.07 Million USD | 17.25% |
| 2021 | -465.78 Million USD | -158.58% |
| 2020 | -243.04 Million USD | -89.97% |
| 2019 | -92.47 Million USD | -358.59% |
| 2018 | 35.36 Million USD | -20.46% |
| 2017 | 45.23 Million USD | 17.29% |
| 2016 | 37.9 Million USD | 94.47% |
| 2015 | 19.49 Million USD | 48.26% |
| 2014 | 13.14 Million USD | 0.49% |
| 2013 | 13.08 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -58.96 Million USD | 0.0% |
| 2024 Q1 | -58.96 Million USD | -14.06% |
| 2023 Q2 | -182.44 Million USD | -87.86% |
| 2023 Q1 | -97.11 Million USD | 59.13% |
| 2023 FY | - USD | 14.76% |
| 2023 Q4 | -133.79 Million USD | -62.89% |
| 2023 Q3 | -82.14 Million USD | 54.98% |
| 2022 Q3 | -118.06 Million USD | 9.87% |
| 2022 Q2 | -130.99 Million USD | -71.5% |
| 2022 Q1 | -76.38 Million USD | 55.36% |
| 2022 FY | - USD | 17.25% |
| 2022 Q4 | -237.63 Million USD | -101.27% |
| 2021 Q4 | -171.12 Million USD | -63.4% |
| 2021 Q1 | -66.05 Million USD | 35.26% |
| 2021 FY | - USD | -158.58% |
| 2021 Q3 | -104.72 Million USD | 18.97% |
| 2021 Q2 | -129.24 Million USD | -95.65% |
| 2020 Q4 | -102.03 Million USD | -98.81% |
| 2020 Q2 | -68.84 Million USD | -91.08% |
| 2020 Q1 | -36.03 Million USD | 55.1% |
| 2020 FY | - USD | -89.97% |
| 2020 Q3 | -51.32 Million USD | 25.45% |
| 2019 Q3 | -39.79 Million USD | -21.31% |
| 2019 Q4 | -80.24 Million USD | -101.62% |
| 2019 FY | - USD | -358.59% |
| 2019 Q1 | -16.38 Million USD | -820.34% |
| 2019 Q2 | -32.8 Million USD | -100.27% |
| 2018 Q3 | -1.78 Million USD | -116.95% |
| 2018 Q2 | 10.5 Million USD | 0.0% |
| 2018 Q4 | -1.78 Million USD | 0.0% |
| 2018 Q1 | 10.5 Million USD | -14.82% |
| 2018 FY | - USD | -20.46% |
| 2017 Q3 | 12.32 Million USD | 14.43% |
| 2017 FY | - USD | 17.29% |
| 2017 Q4 | 12.32 Million USD | 0.0% |
| 2017 Q2 | 10.77 Million USD | 0.0% |
| 2017 Q1 | 10.77 Million USD | 63.23% |
| 2016 Q1 | 8.38 Million USD | 182.36% |
| 2016 FY | - USD | 94.47% |
| 2016 Q4 | 6.6 Million USD | 0.0% |
| 2016 Q3 | 6.6 Million USD | -21.31% |
| 2016 Q2 | 8.38 Million USD | 0.0% |
| 2015 Q3 | 2.97 Million USD | -38.4% |
| 2015 Q1 | 4.82 Million USD | 81.71% |
| 2015 Q4 | 2.97 Million USD | 0.0% |
| 2015 FY | - USD | 48.26% |
| 2015 Q2 | 4.82 Million USD | 0.0% |
| 2014 Q1 | 3.25 Million USD | 0.0% |
| 2014 FY | - USD | 0.49% |
| 2014 Q4 | 2.65 Million USD | 0.0% |
| 2014 Q3 | 2.65 Million USD | -18.45% |
| 2014 Q2 | 3.25 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -250.132% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -4095.03% |
| SQZ Biotechnologies Company | -64.14 Million USD | -287.77% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -1331.891% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 364.488% |
| Mesoblast Limited | -62.38 Million USD | -298.654% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -16092.161% |
| Genus plc | 73.7 Million USD | 437.476% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -3661.913% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -6912.113% |
| Marizyme, Inc. | -34.28 Million USD | -625.522% |
| ContraFect Corporation | -64.99 Million USD | -282.651% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -2735.38% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -5395.113% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -17642.766% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -9305.347% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -10603.046% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -47911.088% |
| Accustem Sciences Inc. | -3.74 Million USD | -6538.86% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -415.727% |
| EV Biologics, Inc. | -1.26 Million USD | -19528.541% |
| Q BioMed Inc. | -617.62 Thousand USD | -40170.117% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 7063.032% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -39229.089% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -10787.315% |
| Biomind Labs Inc. | -1.03 Million USD | -23941.347% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 2618.169% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -3373.118% |
| Skye Bioscience, Inc. | -13.54 Million USD | -1735.9% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -16621.629% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -994778.08% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -6303.168% |
| IMV Inc. | -35.52 Million USD | -600.157% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -1467.257% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -9840.979% |
| GB Sciences, Inc. | -1.41 Million USD | -17416.878% |
| Alpha Cognition Inc. | -9.7 Million USD | -2462.639% |
| HST Global, Inc. | -5303.00 USD | -4690066.321% |
| CSL Limited | 4.78 Billion USD | 105.194% |
| Halberd Corporation | -74.27 Thousand USD | -334745.003% |
| Enzolytics Inc. | -2.12 Million USD | -11620.835% |
| Resverlogix Corp. | -11.74 Million USD | -2018.204% |
| Affymax, Inc. | -14.29 Million USD | -1639.906% |
| SYBLEU INC | -141.57 Thousand USD | -175585.359% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -8020.086% |
| argenx SE | -216.02 Million USD | -15.136% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -349.447% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 20537.101% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -16493.403% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 65752.226% |
| AVAX Technologies, Inc. | -6.11 Million USD | -3968.936% |
| Zenith Capital Corp. | -8.6 Million USD | -2790.071% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1427599.443% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -10066.503% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -141198.352% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -527.496% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -8499.291% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -23671.066% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 3699081.559% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -14112.552% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -12847.998% |
| BioStem Technologies, Inc. | -7.55 Million USD | -3192.709% |
| ONE Bio Corp. | 13.61 Million USD | 1927.068% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -137247.323% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -11991.372% |
| Agentix Corp. | -1.37 Million USD | -18031.469% |
| LadRx Corporation | 412.28 Thousand USD | 60427.377% |
| Cell Source, Inc. | -4.27 Million USD | -5721.369% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -67630.201% |
| Regen BioPharma, Inc. | 1.46 Million USD | 17066.37% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -26445.684% |
| NovAccess Global Inc. | -1.03 Million USD | -23935.586% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 2909.184% |
| Itoco Inc. | -1.86 Million USD | -13207.661% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -65418.023% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -22186.695% |
| Kadimastem Ltd | -2.62 Million USD | -9377.264% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -103901.472% |
| CytoDyn Inc. | -18.02 Million USD | -1279.552% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -314619.306% |
| Mobile Lads Corp. | -2.24 Million USD | -10997.808% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -2033750.029% |
| Qrons Inc. | -40.08 Thousand USD | -620442.202% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -51110.786% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 47256.609% |
| Rebus Holdings, Inc. | -951 Thousand USD | -26053.472% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -23319.697% |
| International Stem Cell Corporation | 202 Thousand USD | 123228.475% |
| Bioxytran, Inc. | -3.82 Million USD | -6410.732% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -472391.489% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -10002.615% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -593.411% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -552610.044% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -8983.985% |
| Neutra Corp. | -181.24 Thousand USD | -137126.834% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -1133.789% |
| PureTech Health plc | -11.62 Million USD | -2039.155% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -1133.874% |
| IXICO plc | -707 Thousand USD | -35079.564% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -3136.428% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -414.457% |
| CSL Limited | 4.73 Billion USD | 105.255% |
| Cellectis S.A. | -92.63 Million USD | -168.491% |